If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 9 Similar Profiles
Endometrial Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Survivors Medicine & Life Sciences
Survival Medicine & Life Sciences
Hysterectomy Medicine & Life Sciences
Ovarian Neoplasms Medicine & Life Sciences
Uterine Neoplasms Medicine & Life Sciences
Referral and Consultation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Publications 2000 2018

  • 694 Citations
  • 14 h-Index
  • 36 Article
  • 1 Comment/debate
  • 1 Review article

Acceptability and feasibility of a Fitbit physical activity monitor for endometrial cancer survivors

Rossi, A., Frechette, L., Miller, D., Miller, E., Friel, C., Van Arsdale, A., Lin, J., Shankar, V., Kuo, D. Y. S. & Nevadunsky, N. S., Jan 1 2018, (Accepted/In press) In : Gynecologic Oncology.

Research output: Contribution to journalArticle

Endometrial Neoplasms
Survivors
Exercise
Leisure Activities
Body Mass Index

Association between diabetes mellitus and progression free survival in women with ovarian granulosa cell tumors

Tymon-Rosario, J. R., Miller, E. M., Gressel, G. M. & Nevadunsky, N. S., Nov 1 2018, In : Gynecologic Oncology Reports. 26, p. 94-98 5 p.

Research output: Contribution to journalArticle

Granulosa Cell Tumor
Disease-Free Survival
Diabetes Mellitus

Palliative Care and Symptom Management for Women with Advanced Ovarian Cancer

Miller, D. & Nevadunsky, N. S., Dec 1 2018, In : Hematology/Oncology Clinics of North America. 32, 6, p. 1087-1102 16 p.

Research output: Contribution to journalReview article

Palliative Care
Ovarian Neoplasms
Assisted Suicide
Hospices
Ascites
Neoadjuvant Therapy
Urban Population
antineoplaston A10
Ovarian Neoplasms
Survival
8 Citations

Randomized Phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu

Fader, A. N., Roque, D. M., Siegel, E., Buza, N., Hui, P., Abdelghany, O., Chambers, S. K., Secord, A. A., Havrilesky, L., O'Malley, D. M., Backes, F., Nevadunsky, N., Edraki, B., Pikaart, D., Lowery, W., El Sahwi, K. S., Celano, P., Bellone, S., Azodi, M., Litkouhi, B. & 4 othersRatner, E., Silasi, D. A., Schwartz, P. E. & Santin, A. D., Jul 10 2018, In : Journal of Clinical Oncology. 36, 20, p. 2044-2051 8 p.

Research output: Contribution to journalArticle

Carboplatin
Paclitaxel
Carcinoma
Disease-Free Survival
ErbB-2 Receptor